Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with <scp>type 2 diabetes</scp> : A post hoc analysis of <scp>SUSTAIN</scp> China
These results support the effectiveness of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg across a broad range of baseline characteristics, in participants with T2D from SUSTAIN China.
Authors
- Ping Hu
- Linong Ji (ORCID: https://orcid.org/0000-0002-3262-2168)
- Yibing Lu (ORCID: https://orcid.org/0000-0002-0018-4714)
- Wenyan Liu (ORCID: https://orcid.org/0000-0002-6714-520X)
- Qiu Zhang (ORCID: https://orcid.org/0000-0002-0204-3528)
- Bimin Shi (ORCID: https://orcid.org/0000-0002-9859-6097)
- Zewei Shen
Institutions
- Anhui Medical University (CN)
- Peking University (CN)
- Soochow University (CN)
- Peking University People's Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1111/dom.15888
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Novo Nordisk